Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...
Biogen acknowledged that in a statement, saying that Qalsody’s continued availability “may be contingent upon verification of clinical benefit in confirmatory trial(s).” VALOR missed its ...
Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a ...
This summary covers key developments in health news, including Mitsubishi Pharma's bidding war, legal actions involving J&J ...
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. After a thorough review of the options trading surrounding ...
Biogen’s more recent offerings are Qalsody (ALS, Ionis), Zurzuvae (postpartum depression, Sage), Skyclarys (Friedreich’s Ataxia, Reata), Leqembi (Alzheimer’s, with partner Eisai), and ...
Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. Following our analysis of the options activities associated with ...